Bacillus subtilis with antibacterial function and application thereof
By screening and identifying Bacillus subtilis JRB-K2, the problems of insufficient antibacterial function of Bacillus subtilis and poor resistance of lactic acid bacteria in the existing technology have been solved, achieving effective inhibition of intestinal pathogens and improving breeding efficiency.
Patent Information
- Application Number
- CN202411319238.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing Bacillus strains are inferior to lactic acid bacteria in terms of antibacterial and immunomodulatory functions, and lactic acid bacteria are sensitive to temperature and pH, which limits their application in feed processing.
A strain of Bacillus subtilis JRB-K2 was screened and identified, which has significant antibacterial ability and stress resistance. It can effectively inhibit intestinal pathogens, improve feed utilization, and maintain a high survival rate in high temperature and artificial gastrointestinal fluid environments.
Bacillus subtilis JRB-K2 significantly inhibits Escherichia coli, Staphylococcus aureus, Salmonella and Clostridium perfringens, improving the efficiency of livestock and poultry farming, enhancing the reproductive performance of sows and the production performance of piglets, and reducing the incidence of diseases.
Smart Images

Figure CN118931800A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of functional microorganism screening and application, and specifically relates to a Bacillus subtilis with antibacterial function and application thereof. Background Art
[0002] Antibiotics play an important role as feed additives in animal husbandry, which can effectively reduce animal diseases and improve production performance. However, with the extensive use of antibiotics in livestock and poultry farming in recent years, its disadvantages have become increasingly apparent, posing a great hidden danger to food safety. Long-term abuse of antibiotics can lead to drug resistance in pathogens, reduce the immune function of animals, and cause imbalance in intestinal flora. It can also cause drug residues in livestock and poultry products and the environment, posing a huge threat to food safety, breeding environment and natural ecology. Therefore, many countries have legislated to restrict the addition and application of antibiotics in the livestock industry. Developing and finding safe and effective green new additives that can replace antibiotics has become a top priority in the research of the feed processing industry.
[0003] Microbial agents are pollution-free and harmless, and are an important development direction for the development of safe feed additives in recent years. Studies have shown that the use of functional microorganisms as feed additives can balance the intestinal flora of animals, regulate intestinal function, improve animal immunity, and improve feed conversion rate. Functional microorganisms have unique therapeutic and conditioning effects and are the most ideal substitute for veterinary antibiotics. Microbial agents are made mainly of probiotics. Probiotics are a type of active microorganisms that are beneficial to the host. They are safe and non-toxic, can protect the intestinal mucosal barrier, maintain the structural balance of intestinal flora, inhibit intestinal inflammation, promote the digestion and absorption of nutrients, inhibit pathogenic bacteria and improve the body's immunity. Commonly used probiotics include lactic acid bacteria, probiotic spore bacteria, yeast, Clostridium butyricum, etc. Among them, lactic acid bacteria is the most common probiotic and has been widely used in humans and animals. In addition, Bacillus is a widely used type of microbial additive in the feed industry. Compared with other types of microorganisms, it has the characteristics of high temperature resistance, acid and alkali resistance, and strong stress resistance, and can still maintain good activity after the feed processing process. Bacillus has the characteristics of rapid growth, rapid reproduction and easy cultivation. It can be applied to large-scale production and promotion. It is a functional microorganism with great development potential. Bacillus can produce dormant spores under adverse conditions, has strong resistance to external harmful factors, grows and reproduces quickly, can prevent the reproduction of pathogens through nutritional competition, and has great application potential in the field of antibacterial.
[0004] The current problem is that most Bacillus species have good stress resistance, but their antibacterial and immunomodulatory functions are not as good as those of lactic acid bacteria. Although lactic acid bacteria have good antibacterial and immunomodulatory functions, they are sensitive to temperature, acid and alkali, and have poor stress resistance, which limits their actual application effect in feed processing. Summary of the invention
[0005] The present invention provides a Bacillus subtilis strain to solve the problems of the prior art, and provides the application of the strain in livestock and poultry breeding. The Bacillus subtilis strain can effectively inhibit intestinal pathogens, prevent and treat intestinal inflammation, improve feed utilization, improve breeding benefits, and has excellent stress resistance and great application potential.
[0006] The first object of the present invention is to provide a strain of Bacillus subtilis JRB-K2, which has been deposited in the China General Microbiological Culture Collection Center on July 31, 2024, with a deposit number of CGMCCNO.31500, and a deposit address of No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0007] The rDNA sequence of the Bacillus subtilis JRB-K2 is SEQ ID NO: 1.
[0008] The second object of the present invention is to provide an application of the screened Bacillus subtilis in the preparation of antibacterial products;
[0009] The antibacterial product, as specifically described in the examples, is Escherichia coli, Staphylococcus aureus, Salmonella or Clostridium perfringens.
[0010] The present invention also provides another use of the screened Bacillus subtilis, which is use as a feed additive.
[0011] In yet another aspect, the present invention provides an antibacterial product comprising the screened Bacillus subtilis.
[0012] The invention also provides a feed for livestock and poultry breeding, wherein the selected Bacillus subtilis is added.
[0013] The Bacillus subtilis JRB-K2 selected by the present invention has a significant inhibitory effect on various pathogens such as Escherichia coli, Staphylococcus aureus, Salmonella, Clostridium perfringens, etc., especially the inhibitory effect on Clostridium perfringens is the most obvious, and the diameter of the inhibition zone reaches 24.56mm. The selected Bacillus subtilis JRB-K2 can withstand high temperatures. After being warmed at 85 degrees for 2 minutes and 95 degrees for 2 minutes, which are close to the feed pelleting temperature, the survival rates are 97.5% and 95.0% respectively. The strain also has a strong tolerance to artificial gastrointestinal fluid. The survival rates after being warmed in artificial gastric fluid for 1 hour and 2 hours are 100% and 97.5% respectively; the survival rates after being warmed in artificial intestinal fluid for 1 hour and 2 hours are both 100%. The Bacillus subtilis JRB-K2 selected by the present invention is applied to livestock and poultry breeding as a microbial feed additive, and the effect is obvious. This strain can effectively inhibit intestinal inflammation caused by pathogenic bacteria such as Escherichia coli, Salmonella, Clostridium perfringens, promote animal digestion, improve feed utilization, and improve breeding benefits. It has broad application prospects in the research of microbial feed additives. The addition of the strain described in the present invention can effectively enhance the breeding performance of sows and improve the production performance and disease resistance of piglets. Compared with the control group, the number of live piglets produced by sows in the experimental group fed with Bacillus subtilis JRB-K2 was 7.39% higher, the newborn litter weight was 8.49% higher, the average weight at 21 days of age was 8.56% higher, the survival rate was 3.66% higher, and the incidence of yellow diarrhea, white diarrhea and other diseases was also significantly reduced. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 : Colony morphology of Bacillus subtilis JRB-K2 on LB medium.
[0015] Figure 2 :Bacillus subtilis JRB-K2 bacterial morphology under microscope.
[0016] Figure 3 :Bacillus subtilis JRB-K2 antibacterial effect diagram under different culture time and conditions;
[0017] Figure 4 :The antibacterial function of different strains against Clostridium perfringens. DETAILED DESCRIPTION
[0018] The present invention screened and obtained a Bacillus strain which can inhibit the growth of pathogenic bacteria and has excellent stress resistance, and carried out biological characteristic analysis and antibacterial function verification on it, and determined that the screened strain can be used as an antibacterial feeding microorganism with excellent stress resistance.
[0019] The present invention is further described below by means of specific examples, but the protection scope of the present invention shall not be limited thereto.
[0020] Example 1: Isolation and screening of strains
[0021] The method for obtaining the Bacillus subtilis JRB-K2 is as follows:
[0022] 1. Sample source:
[0023] Intestinal feces of pigs from Haiyang farm in Yantai City, Shandong Province, and intestinal feces of pigs from Feixian farm in Linyi City.
[0024] 2. Strain isolation and screening:
[0025] Screen the strains from the intestinal feces samples of healthy pigs, take 1g of sample, add 9mL of sterile saline, shake and mix for 5min to make the initial bacterial suspension, place the bacterial suspension in an 80-degree water bath, warm it for 10 minutes, cool it quickly, and then dilute the sample in 10-fold increments with saline. Select 3-5 appropriate dilutions, take 100μL of each dilution and spread it on the LB medium plate, and invert it in a 37-degree constant temperature incubator for overnight culture.
[0026] A total of 10 colonies with good growth status and different morphologies on different plates were selected, and they were streaked multiple times on LB medium plates to separate and purify them to obtain pure cultures, which were named K1-10 respectively.
[0027] 3. Initial screening of antibacterial ability
[0028] The 10 selected bacterial strains were inoculated into LB liquid culture medium, cultured at 37°C for 48 hours, and the fermentation supernatant was obtained by centrifugation. The antibacterial ability of the fermentation supernatant of each strain against pathogenic bacteria was detected by the agar punch method. The results are shown in the following table.
[0029] Table 1: Analysis results of antibacterial performance of different strains
[0030]
[0031]
[0032] From the results in Table 1, it can be seen that K2, K3, and K8 have the best inhibitory effect on Escherichia coli; K1, K2, and K5 have the best inhibitory effect on Staphylococcus aureus; K2 and K8 have the best inhibitory effect on Salmonella; and K1, K2, and K5 have the most obvious inhibitory effect on Clostridium perfringens.
[0033] 4. Temperature tolerance screening
[0034] The above 10 strains were inoculated into LB liquid culture medium respectively, cultured at 37℃ for 72h, and then placed in a water bath at 80℃ for 10min to kill the vegetative bodies and leave the spores. The heat resistance of the spores of this strain was evaluated. The temperature conditions were 85℃ for 2min and 95℃ for 2min, which are close to the feed pelleting temperature. The plates were coated before and after heat treatment, and the survival rate was calculated.
[0035] Table 2: Analysis results of heat resistance of different strains
[0036]
[0037]
[0038] From the above results, it can be seen that strains K2, K4, K5, and K8 have better tolerance to high temperature. Combined with the antibacterial ability of each strain, strains K2, K5, and K8 were selected for the next experiment.
[0039] 5. Drug sensitivity test
[0040] The strains K2, K5, and K8 were activated by overnight culture in LB liquid, and the samples were evenly spread on the LB plate. After the bacterial solution was absorbed for 5 minutes, each drug-sensitive sheet was taken with sterile tweezers and attached to the surface of the plate culture medium. The drug-sensitive sheet was pressed several times with tweezers to make it closely attached to the culture medium. The plate was placed in a 37-degree incubator for overnight culture, and the diameter of the inhibition zone (mm) was measured with a vernier caliper the next day. The concentrations of various drugs contained in the drug-sensitive sheets used in the experiment were greater than or equal to the concentrations of drugs commonly used in animal husbandry, so as to analyze the sensitivity of the strains to drugs in practical applications.
[0041] Table 3: Results of drug sensitivity tests for different strains
[0042]
[0043]
[0044] At present, several drugs commonly used by breeding companies include streptomycin, penicillin, gentamicin, kanamycin, amoxicillin, ampicillin, lincomycin, norfloxacin, etc. From the results in the above table, it can be seen that the K2 strain has good tolerance to drugs and is less affected by drugs in practical applications. Therefore, the K2 strain was selected as the target strain. The K2 strain was named JRB-K2 and further evaluated.
[0045] Example 2 Identification of strains
[0046] 1. Colony morphology identification
[0047] The colony morphology of JRB-K2 strain is as follows Figure 1 As shown, the colonies are round, with a rough and wrinkled surface, milky white and opaque, and contain mucus.
[0048] 2. 16S rDNA Identification of Bacterial Species
[0049] After the strain was isolated and purified by streaking, a single colony was picked and inoculated into LB liquid medium for culture. The strain DNA was extracted using a bacterial genome extraction kit and used as a template for PCR amplification. The PCR reaction conditions were as follows: 98℃ pre-denaturation for 5min, 95℃ for 30s, 55℃ for 30s, 72℃ for 30s, 30 cycles, and final extension at 72℃ for 10min. The PCR product was sequenced and the results were compared with the known sequences in the Genbank database for homology, indicating that JRB-K2 was Bacillus subtilis.
[0050] The final strain obtained by screening was Bacillus subtilis B. subtilis JRB-K2, which was deposited in the China General Microbiological Culture Collection Center on July 31, 2024, with the deposit number CGMCC NO.31500, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0051] Figure 1 This is the colony morphology of Bacillus subtilis JRB-K2 on LB medium. The colonies are round, with wrinkles on the surface and are milky white and opaque. Figure 2 The bacterial morphology of the strain under a microscope. After culturing in LB medium for 24 hours, the bacteria are in the shape of slender rods. After culturing for 48 hours, microscopic examination shows that the bacteria have formed endospores, which are located in the center of the bacteria.
[0052] Example 3 Analysis of antibacterial ability of Bacillus subtilis JRB-K2
[0053] 1. Preparation of test bacterial solution
[0054] The Bacillus subtilis JRB-K2 of the present invention is inoculated into LB medium, and cultured at 37°C, 250r / min, with shaking for 48, 72, and 96h, respectively, and centrifuged at 12000r for 5min to obtain the fermentation supernatant for use. In order to investigate the difference in the antibacterial function of the strain under different dissolved oxygen conditions, the present invention also prepares two samples with less dissolved oxygen during the culture process, namely, sample YK bottles and YK tubes, and uses conical bottles and EP tubes for anaerobic culture, respectively, the sample volume of the 100ml conical bottle is 90ml, the sample volume of the 5ml EP tube is 4ml, the inoculation amount is 2%, and after static culture for 72h, the supernatant is centrifuged for use.
[0055] 2. Antibacterial ability analysis
[0056] The antibacterial performance analysis was carried out using Escherichia coli (ATCC25922), Staphylococcus aureus (ATCC12600), Salmonella (ATCC1791), and Clostridium perfringens (ATCC13124) stored in this laboratory as indicator bacteria. Each indicator bacteria was inoculated into LB medium, cultured at 37°C, 250r / min for 16-18h and then used.
[0057] The antibacterial properties of the strains were evaluated using the Oxford cup agar punching method. Take a sterile plate, pour 10-15mL of LB culture medium, and spread it evenly in the plate as the bottom layer. After it solidifies, place the sterilized Oxford cup on the agar (5-7 Oxford cups can be placed at equal distances in each culture dish). Take an appropriate amount of sterile semi-solid LB culture medium (agar content is 1%), cool it to 50±5℃, add 0.25mL of pathogenic bacteria suspension with an OD600 absorbance value of 0.1 to every 25mL of culture medium, gently shake and flatten it as the bacterial layer. After the agar cools and solidifies, use tweezers to remove the Oxford cup, draw 150uL of the sample to be tested and add it to the corresponding hole, culture it overnight at 37℃, measure the diameter of each inhibition zone, and judge the antibacterial effect of the sample.
[0058] The antibacterial effects of Bacillus subtilis JRB-K2 on four pathogens under different culture times and conditions are as follows Figure 3 As shown in Table 4:
[0059] Table 4: Antibacterial effect of Bacillus subtilis JRB-K2 under different culture time and conditions
[0060]
[0061] Figure 3 From left to right in the figure are the inhibition circles of the strains screened by the present invention against Escherichia coli, Staphylococcus aureus, Salmonella and Clostridium perfringens. It can be seen from the results of the chart that the inhibition circle of the fermentation supernatant obtained after the strain was cultured for 72 hours is the largest. The diameters of the inhibition circles of the 72h fermentation supernatant against Escherichia coli, Staphylococcus aureus, Salmonella and Clostridium perfringens are 14.18mm, 17.35mm, 15.33mm and 24.56mm respectively. It can be seen that the Bacillus subtilis JRB-K2 screened by the present invention has obvious antibacterial effects on the four pathogens, especially the strongest antibacterial effect on Clostridium perfringens, with an inhibition circle diameter of 24.56mm, and the effect is very significant. In addition, the two samples of YK bottle and YK tube obtained by culture under relatively anaerobic conditions have low bacterial concentration and low antibacterial effect, which is not as good as the samples obtained under normal dissolved oxygen.
[0062] The strains described in the present invention were compared with several strains screened from commercially available antibacterial products stored in the laboratory. Each strain was cultured in liquid and centrifuged to obtain the supernatant. The Oxford agar punch method was used to evaluate the inhibitory ability of each strain against Clostridium perfringens. The results are as follows: Figure 4As shown in Table 5, No. 1 is the Bacillus subtilis JRB-K2 of the present invention, No. 2 is Bacillus subtilis cqy5, No. 3 is Lactobacillus rhamnosus cbb3, No. 4 is Bacillus amyloliquefaciens ber8, No. 5 is Bacillus subtilis yc1, and No. 6 is Pediococcus acidilactici yld4. Among them, No. 1 has the largest inhibition zone against Clostridium perfringens, which is 24.17 mm. It can be seen that compared with several other strains with the same antibacterial function, the Bacillus subtilis JRB-K2 screened by the present invention has a more significant inhibitory effect on Clostridium perfringens.
[0063] Table 5: Data table of the inhibitory effect of different strains on Clostridium perfringens
[0064] Inhibition zone (mm) 1 2 3 4 5 6 Clostridium perfringens 24.17 20.12 18.93 19.22 16.36 13.62
[0065] Example 4 Tolerance test of Bacillus subtilis JRB-K2 to artificial gastric juice and intestinal juice
[0066] 1. Tolerance to artificial gastric juice
[0067] Bacillus subtilis JRB-K2 was inoculated into LB liquid medium, and the spore formation rate was examined under a microscope after 48 hours of culture. When the strain produced more than 50% spores, the vegetative body was killed in a water bath at 80 degrees for 10 minutes, and the remaining spores were used to evaluate the acid resistance of the spores of the strain. Artificial gastric acid was sterile distilled water with a pH of 3.2. 1g of pepsin was added to every 100mL to prepare artificial gastric juice. 9mL of artificial gastric juice was added to 1mL of sample and heated at 40 degrees for 1h and 2h. The survival rate was calculated by coating the plate before and after treatment.
[0068] 2. Tolerance to artificial intestinal fluid
[0069] Bacillus subtilis JRB-K2 was inoculated into LB liquid medium, and the spore formation rate was examined under a microscope after 48 hours of culture. When the strain produced more than 50% spores, the vegetative body was killed in a water bath at 80 degrees for 10 minutes, and the remaining spores were used to evaluate the bile salt tolerance of the spores of the strain. Artificial intestinal fluid was 0.6800g of potassium dihydrogen phosphate added to 100mL of distilled water, and 0.3000g of pig bile salt was added after adjusting the pH to 6.8, and sterilized at 121℃ for 15min. 1mL of sample was added to 9mL of artificial intestinal fluid, and the samples were heated at 40 degrees for 1h and 2h. The survival rate was calculated by coating the plates before and after treatment. The results are shown in Table 6 below.
[0070] Table 6: Tolerance of Bacillus subtilis JRB-K2 to artificial gastrointestinal fluid
[0071]
[0072]
[0073] The above results show that the survival rate of the Bacillus subtilis JRB-K2 of the present invention after being warmed in artificial gastric juice for 1 hour is 100%, and the survival rate after being warmed in artificial intestinal juice for 2 hours is 97.5%; the survival rate after being warmed in artificial intestinal juice for 1 hour and 2 hours is 100%, indicating that the strain has strong tolerance to artificial gastrointestinal juice.
[0074] Example 5 Genetic stability analysis of Bacillus subtilis JRB-K2
[0075] Bacillus subtilis JRB-K2 was subcultured more than ten times to detect the stability of its antibacterial properties. The strain was fermented in LB for 24 hours, and the supernatant was obtained by centrifugation for further evaluation. The indicator bacteria were Escherichia coli, Staphylococcus aureus, Salmonella, Clostridium perfringens 2027 (chicken source), Clostridium perfringens 2038 (pig source), and Proteus. In the following table, JRB-K2 is the original strain, and KN is the strain after ten subcultures.
[0076] Table 7: Genetic stability of Bacillus subtilis JRB-K2
[0077]
[0078] From the above results, it can be seen that after multiple subcultures, the inhibitory ability of Bacillus subtilis against several pathogenic bacteria is not much different, and the stability of its antibacterial performance is relatively good.
[0079] Example 6 Effect of Bacillus subtilis JRB-K2 on sow reproductive performance and piglet growth
[0080] The experiment was conducted at a farm in Fei County, Linyi, Shandong Province. 48 healthy sows with normal growth and similar due dates were randomly divided into two groups (control group and experimental group), with 4 replicates in each group and 6 sows in each replicate. The sows were fed the corresponding diet according to the design plan from one month before delivery until 21 days after delivery. The control group was fed a basic diet, and the experimental group was fed a basic diet supplemented with 0.2% Bacillus subtilis JRB-K2 powder (10 10 CFU / g). During the experimental period, the sows’ feeding and reproduction conditions were recorded. After the experiment, the sows were weighed and the feed intake, litter size, live piglets, and stillbirths of each experimental group were calculated. The specific results are as follows:
[0081] Table 8: Effect of Bacillus subtilis JRB-K2 on sow reproductive performance
[0082]
[0083] As shown in Table 8 above, the total number of piglets born in the experimental group was 5.62% higher than that in the control group, the number of live piglets was 7.39% higher, the litter weight at birth was 8.49% higher, and the feed intake was 7.77% higher.
[0084] The immune protection of piglets before weaning is mainly obtained from breast milk, so the health of the sow will affect the condition of the piglets. The effect of adding Bacillus subtilis JRB-K2 to the sow's diet on the growth of suckling piglets is shown in Table 9 below.
[0085] Table 9: Effect of Bacillus subtilis JRB-K2 on the growth of suckling piglets
[0086]
[0087] The average birth weight of piglets in the experimental group was 2.76% higher than that in the control group, the average weight at 21 days of age was 8.56% higher, and the survival rate was 3.66% higher. In addition, the piglets in the experimental group had 16% lower yellow scour, 8% lower white scour, and 9% lower other diseases than those in the control group. The experimental results show that the addition of Bacillus subtilis can effectively enhance the reproductive performance of sows and improve the production performance and disease resistance of piglets.
[0088] In summary, the Bacillus subtilis JRB-K2 of the present invention can effectively inhibit common intestinal pathogens such as Escherichia coli, Salmonella, Clostridium perfringens, etc., and can also promote animal digestion, improve feed utilization, and improve breeding efficiency. It has broad application prospects in the research of microbial feed additives.
Claims
1. A Bacillus subtilis, It is characterized in that The deposit number of the Bacillus subtilis is CGMCCNO.31500.
2. The Bacillus subtilis according to claim 1, It is characterized in that The rDNA sequence of Bacillus subtilis is SEQ ID NO:
1.
3. Use of the Bacillus subtilis according to claim 1 in the preparation of antibacterial products.
4. The use according to claim 3, It is characterized in that The antibacterial product is an antibacterial product for Escherichia coli, Staphylococcus aureus, Salmonella or Clostridium perfringens.
5. Use of the Bacillus subtilis according to claim 1 as a feed additive.
6. The use according to claim 5, It is characterized in that The feed additive is a feed additive used for livestock and poultry breeding.
7. An antibacterial product, It is characterized in that The antibacterial product contains the Bacillus subtilis according to claim 1.
8. A feed for livestock and poultry breeding, It is characterized in that The feed is added with the Bacillus subtilis spores according to claim 1.
Citation Information
Patent Citations
Bacillus subtilis and application thereof
CN111187730A
Multi-effect bacillus subtilis for high yield of immune polysaccharide and bacteriocin and application
CN111961617A
Bacillus subtilis SLY1927 and application thereof
CN116024145A
Bacillus subtilis JBH-BK8 and application thereof
CN117511802A
Cited By
Application of antibacterial culture of bacillus subtilis BS-N in preparation of food antibacterial agent, antibacterial food and preparation method of antibacterial food
CN122556541A
Bacillus subtilis BS-N, microbial preparation containing bacillus subtilis BS-N, preparation method of bacillus subtilis, bacteriostatic culture, preparation method and application of bacteriostatic culture, and bacteriostatic agent
CN122563814A
